{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:29:53Z","timestamp":1793312993388,"version":"4.5.0"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004569","name":"Ministerstwo Edukacji i Nauki","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007835","name":"Silesian University of Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007835","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ejphar.2025.177644","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T17:07:00Z","timestamp":1745514420000},"page":"177644","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Antisense oligonucleotides: A promising advancement in neurodegenerative disease treatment"],"prefix":"10.1016","volume":"999","author":[{"given":"Katarzyna","family":"Dudzisz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Wandzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.177644_bib1","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1474-4422(23)00334-4","article-title":"Hereditary transthyretin amyloid neuropathies: advances in pathophysiology, biomarkers, and treatment","volume":"22","author":"Adams","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2025.177644_bib2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ncrna.2023.06.002","article-title":"Non-coding RNA therapeutics in cardiovascular diseases and risk factors: systematic review","volume":"8","author":"Ardiana","year":"2023","journal-title":"Non-coding RNA Research"},{"key":"10.1016\/j.ejphar.2025.177644_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12408","article-title":"Projected increase in amyotrophic lateral sclerosis from 2015 to 2040","volume":"7","author":"Arthur","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2025.177644_bib4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.14108","article-title":"Parkinson disease","volume":"27","author":"Balestrino","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ejphar.2025.177644_bib96","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1126\/science.abq5622","article-title":"Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies","volume":"379","author":"Baughn","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2025.177644_bib5","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1007\/s13311-022-01237-4","article-title":"Design of a randomized, Placebo-Controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS study","volume":"19","author":"Benatar","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejphar.2025.177644_bib95","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1146\/annurev-pharmtox-010919-023738","article-title":"Antisense Drugs Make Sense for Neurological Diseases","volume":"61","author":"Bennett","year":"2021","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejphar.2025.177644_bib94","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-neuro-070918-050501","article-title":"Antisense Oligonucleotide Therapies for Neurodegenerative Diseases","volume":"42","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.ejphar.2025.177644_bib6","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40265-023-01904-6","article-title":"Tofersen: first approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2025.177644_bib7","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s13311-022-01247-2","article-title":"Antisense oligonucleotides for the study and treatment of ALS","volume":"19","author":"Boros","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejphar.2025.177644_bib8","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.3390\/ijms22157896","article-title":"Genomic variability in the survival motor neuron genes (SMN1 and SMN2): implications for spinal muscular atrophy phenotype and therapeutics development","volume":"22","author":"Butchbach","year":"2021","journal-title":"IJMS"},{"key":"10.1016\/j.ejphar.2025.177644_bib9","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020106389","article-title":"Proteostatic imbalance and protein spreading in amyotrophic lateral sclerosis","volume":"40","author":"Cicardi","year":"2021","journal-title":"EMBO J."},{"key":"10.1016\/j.ejphar.2025.177644_bib10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.molmed.2022.02.006","article-title":"InFUSing antisense oligonucleotides for treating ALS","volume":"28","author":"Codron","year":"2022","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejphar.2025.177644_bib11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.27853","article-title":"Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5\u2010Year update of the NURTURE study","volume":"68","author":"Crawford","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejphar.2025.177644_bib12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense technology: an overview and prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2025.177644_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171127","article-title":"The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain","volume":"12","author":"Datson","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2025.177644_bib14","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ejphar.2025.177644_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105642","article-title":"Recent developments in the management of Huntington's disease","volume":"120","author":"Devadiga","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejphar.2025.177644_bib16","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1111\/bcp.15468","article-title":"Population pharmacokinetic\/pharmacodynamic modelling of eplontersen, an antisense oligonucleotide in development for transthyretin amyloidosis","volume":"88","author":"Diep","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177644_bib17","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028035","article-title":"Pathology of neurodegenerative diseases","volume":"9","author":"Dugger","year":"2017","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.ejphar.2025.177644_bib18","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s40120-024-00614-9","article-title":"Pharmacotherapies for the treatment of progressive supranuclear palsy: a narrative review","volume":"13","author":"Dunning","year":"2024","journal-title":"Neurol Ther"},{"key":"10.1016\/j.ejphar.2025.177644_bib19","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.addr.2015.03.008","article-title":"Antisense oligonucleotides in therapy for neurodegenerative disorders","volume":"87","author":"Evers","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejphar.2025.177644_bib20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3390\/brainsci12020161","article-title":"Understanding the burdens associated with Huntington's disease in manifest patients and care partners\u2013comparing to parkinson's disease and the general population","volume":"12","author":"Exuzides","year":"2022","journal-title":"Brain Sci."},{"key":"10.1016\/j.ejphar.2025.177644_bib21","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0140-6736(22)01272-7","article-title":"Amyotrophic lateral sclerosis","volume":"400","author":"Feldman","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.177644_bib22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/0192623314551840","article-title":"Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective","volume":"43","author":"Frazier","year":"2015","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ejphar.2025.177644_bib23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/ph12020078","article-title":"Tegsedi (Inotersen): an antisense oligonucleotide approved for the treatment of adult patients with hereditary transthyretin amyloidosis","volume":"12","author":"Gales","year":"2019","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejphar.2025.177644_bib24","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson's disease, 1990\u20132016: a systematic analysis for the global Burden of Disease Study 2016","volume":"17","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2025.177644_bib25","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","article-title":"Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the global Burden of Disease Study 2021","volume":"23","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2025.177644_bib27","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1474-4422(21)00414-2","article-title":"Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis","volume":"21","author":"Goutman","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2025.177644_bib28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.drudis.2017.09.018","article-title":"Locked nucleic acid: modality, diversity, and drug discovery","volume":"23","author":"Hagedorn","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejphar.2025.177644_bib29","doi-asserted-by":"crossref","first-page":"803","DOI":"10.4103\/NRR.NRR-D-23-02057","article-title":"Antisense oligonucleotides provide optimism to the therapeutic landscape for tauopathies","volume":"20","author":"Harris","year":"2025","journal-title":"Neural Regener. Res."},{"key":"10.1016\/j.ejphar.2025.177644_bib30","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1093\/nar\/gkw533","article-title":"Splice-switching antisense oligonucleotides as therapeutic drugs","volume":"44","author":"Havens","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2025.177644_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/hlca.202200169","article-title":"The MOE modification of RNA: origins and widescale impact on the Oligonucleotide therapeutics field","volume":"106","author":"Hill","year":"2023","journal-title":"Helv. Chim. Acta"},{"key":"10.1016\/j.ejphar.2025.177644_bib32","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1080\/15476286.2022.2066334","article-title":"Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases","volume":"19","author":"Holm","year":"2022","journal-title":"RNA Biol."},{"key":"10.1016\/j.ejphar.2025.177644_bib33","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","article-title":"Nusinersen: first global approval","volume":"77","author":"Hoy","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2025.177644_bib35","article-title":"Rethinking antisense oligonucleotide therapeutics for amyotrophic lateral sclerosis","volume":"acn3","author":"Ito","year":"2024","journal-title":"Ann. Clin. Trans. Neurol."},{"key":"10.1016\/j.ejphar.2025.177644_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102246","article-title":"Preclinical evaluation of stereopure antisense oligonucleotides for allele-selective lowering of mutant HTT","volume":"35","author":"Iwamoto","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejphar.2025.177644_bib37","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.3390\/biomedicines10061432","article-title":"Molecular pathophysiological mechanisms in Huntington's disease","volume":"10","author":"Jurcau","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejphar.2025.177644_bib38","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1093\/nar\/gkac037","article-title":"Impact of guanidine-containing backbone linkages on stereopure antisense oligonucleotides in the CNS","volume":"50","author":"Kandasamy","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2025.177644_bib39","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3390\/biom13050788","article-title":"Therapeutic strategies for spinocerebellar ataxia type 1","volume":"13","author":"Kerkhof","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejphar.2025.177644_bib40","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3390\/cells13221869","article-title":"Clinical applications of antisense oligonucleotides in cancer: a focus on glioblastoma","volume":"13","author":"Khuu","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2025.177644_bib41","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4062\/biomolther.2023.001","article-title":"Drug discovery perspectives of antisense oligonucleotides","volume":"31","author":"Kim","year":"2023","journal-title":"Biomol. Ther. (Seoul)"},{"key":"10.1016\/j.ejphar.2025.177644_bib42","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.omtn.2019.07.004","article-title":"Suppression of mutant protein expression in SCA3 and SCA1 Mice using a CAG repeat-targeting antisense oligonucleotide","volume":"17","author":"Kourkouta","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejphar.2025.177644_bib43","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3390\/biom13030453","article-title":"The amyloid Cascade Hypothesis in alzheimer's disease: should we change our thinking?","volume":"13","author":"Kurkinen","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejphar.2025.177644_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107083","article-title":"Metabolic disorders affecting the liver and heart: therapeutic efficacy of miRNA-based therapies?","volume":"201","author":"La Sala","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2025.177644_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.956440","article-title":"Worldwide trends in mortality related to Parkinson's disease in the period of 1994\u20132019: analysis of vital registration data from the WHO Mortality database","volume":"13","author":"Lampropoulos","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejphar.2025.177644_bib46","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aba4624","article-title":"Antisense oligonucleotides for neurodegeneration","volume":"367","author":"Leavitt","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2025.177644_bib47","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s12265-013-9495-7","article-title":"Antisense technology: an emerging platform for cardiovascular disease therapeutics","volume":"6","author":"Lee","year":"2013","journal-title":"J. of Cardiovasc. Trans. Res."},{"key":"10.1016\/j.ejphar.2025.177644_bib48","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1007\/s00415-024-12269-5","article-title":"Multiple system atrophy: an update and emerging directions of biomarkers and clinical trials","volume":"271","author":"Liu","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.ejphar.2025.177644_bib49","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","article-title":"Spinal muscular atrophy","volume":"371","author":"Lunn","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.177644_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.852003","article-title":"Alpha-synuclein targeting therapeutics for parkinson's disease and related synucleinopathies","volume":"13","author":"Menon","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejphar.2025.177644_bib51","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus Sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2025.177644_bib52","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1523\/JNEUROSCI.5384-11.2012","article-title":"Alexander disease","volume":"32","author":"Messing","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2025.177644_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00443","article-title":"Gene therapy for the leukodystrophies: from preclinical animal studies to clinical trials","volume":"21","author":"Metovic","year":"2024","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejphar.2025.177644_bib54","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2025.177644_bib55","series-title":"Presented at the Oligonucleotides for CNS Summit","article-title":"Preclinical development of AMX0114, an antisense oligonucleotide targeting Calpain-2","author":"Mizerak","year":"2024"},{"key":"10.1016\/j.ejphar.2025.177644_bib56","doi-asserted-by":"crossref","first-page":"14514","DOI":"10.1016\/S0021-9258(19)85268-7","article-title":"Evaluation of 2\u2018-modified oligonucleotides containing 2\u2018-deoxy gaps as antisense inhibitors of gene expression","volume":"268","author":"Monia","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2025.177644_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103487","article-title":"Hyperphosphorylated tau (p-tau) and drug discovery in the context of Alzheimer's disease and related tauopathies","volume":"28","author":"Moore","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejphar.2025.177644_bib58","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3390\/genes15101342","article-title":"Recent progress of antisense oligonucleotide therapy for Superoxide-Dismutase-1-Mutated amyotrophic lateral sclerosis: focus on tofersen","volume":"15","author":"Moriyama","year":"2024","journal-title":"Genes"},{"key":"10.1016\/j.ejphar.2025.177644_bib59","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","article-title":"The pathogenesis of Parkinson's disease","volume":"403","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.177644_bib60","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","article-title":"Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial","volume":"29","author":"Mummery","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2025.177644_bib61","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3390\/molecules23061302","article-title":"A half-century history of applications of antisense oligonucleotides in medicine, agriculture and forestry: we should continue the journey","volume":"23","author":"Oberemok","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2025.177644_bib62","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.4103\/1673-5374.369097","article-title":"Alexander disease: the road ahead","volume":"18","author":"Pajares","year":"2023","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.ejphar.2025.177644_bib63","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3390\/biom10060912","article-title":"The future of targeted gene-based treatment strategies and biomarkers in parkinson's disease","volume":"10","author":"Polissidis","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejphar.2025.177644_bib64","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1089\/hum.2012.225","article-title":"Antisense oligonucleotides for the treatment of spinal muscular atrophy","volume":"24","author":"Porensky","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ejphar.2025.177644_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biom10010001","article-title":"Characterization of the prion protein binding properties of antisense oligonucleotides","volume":"10","author":"Reidenbach","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejphar.2025.177644_bib67","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","article-title":"Antisense oligonucleotides: the next frontier for treatment of neurological disorders","volume":"14","author":"Rinaldi","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejphar.2025.177644_bib68","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2025.177644_bib69","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.4103\/1673-5374.385285","article-title":"Antisense therapy: a potential breakthrough in the treatment of neurodegenerative diseases","volume":"19","author":"Romano","year":"2024","journal-title":"Neural Regener. Res."},{"key":"10.1016\/j.ejphar.2025.177644_bib70","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11910-024-01345-y","article-title":"Huntington's disease: latest frontiers in therapeutics","volume":"24","author":"Saade","year":"2024","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.ejphar.2025.177644_bib71","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16140","article-title":"Breaking barriers with tofersen: enhancing therapeutic opportunities in amyotrophic lateral sclerosis","volume":"31","author":"Saini","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ejphar.2025.177644_bib72","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s40259-024-00665-2","article-title":"Mechanisms of action of the US food and Drug administration-approved antisense oligonucleotide drugs","volume":"38","author":"Sang","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejphar.2025.177644_bib73","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3390\/biomedicines10081906","article-title":"The journey of human transthyretin: synthesis, structure stability, and catabolism","volume":"10","author":"Sanguinetti","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejphar.2025.177644_bib74","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.177644_bib75","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1093\/eurheartj\/ehac463","article-title":"Small non-coding RNA therapeutics for cardiovascular disease","volume":"43","author":"Shah","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2025.177644_bib76","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/s41587-021-00955-y","article-title":"Questions swirl around failures of disease-modifying Huntington's drugs","volume":"39","author":"Sheridan","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejphar.2025.177644_bib77","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1146\/annurev-pharmtox-010818-021050","article-title":"Therapeutic oligonucleotides: state of the art","volume":"59","author":"Smith","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejphar.2025.177644_bib78","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.3390\/ijms25073984","article-title":"Spinocerebellar Ataxia type 3 Pathophysiology\u2014Implications for translational research and clinical studies","volume":"25","author":"Stahl","year":"2024","journal-title":"IJMS"},{"key":"10.1016\/j.ejphar.2025.177644_bib79","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.ymthe.2017.03.023","article-title":"FDA-Approved Oligonucleotide therapies in 2017","volume":"25","author":"Stein","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejphar.2025.177644_bib80","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/scientificamerican1198-46b","article-title":"Shutting Down the gene","volume":"279","author":"Stix","year":"1998","journal-title":"Sci. Am."},{"key":"10.1016\/j.ejphar.2025.177644_bib81","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.mib.2016.05.017","article-title":"Antisense antimicrobial therapeutics","volume":"33","author":"Sully","year":"2016","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.ejphar.2025.177644_bib82","doi-asserted-by":"crossref","DOI":"10.1172\/JCI186116","article-title":"The expanding application of antisense oligonucleotides to neurodegenerative diseases","volume":"134","author":"Sumner","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2025.177644_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1034072","article-title":"miRNA and antisense oligonucleotide-based \u03b1-synuclein targeting as disease-modifying therapeutics in Parkinson's disease","volume":"13","author":"Suvarna","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177644_bib84","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","article-title":"Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2025.177644_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2022.101628","article-title":"Pathophysiology of neurodegenerative diseases: an interplay among axonal transport failure, oxidative stress, and inflammation?","volume":"59","author":"Tesco","year":"2022","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.ejphar.2025.177644_bib86","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41591-021-01557-6","article-title":"Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide","volume":"28","author":"Tran","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2025.177644_bib87","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1474-4422(24)00216-3","article-title":"Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study","volume":"23","author":"Van Den Berg","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2025.177644_bib88","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1146\/annurev-neuro-100720-034518","article-title":"Parkinson's disease genetics and pathophysiology","volume":"44","author":"V\u00e1zquez-V\u00e9lez","year":"2021","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.ejphar.2025.177644_bib89","article-title":"Recent progress of the genetics of amyotrophic lateral sclerosis and challenges of gene therapy","volume":"17","author":"Wang","year":"2023","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ejphar.2025.177644_bib90","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","article-title":"Hallmarks of neurodegenerative diseases","volume":"186","author":"Wilson","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2025.177644_bib91","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1073\/pnas.75.1.280","article-title":"Inhibition of rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide","volume":"75","author":"Zamecnik","year":"1978","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejphar.2025.177644_bib92","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13024-022-00533-z","article-title":"Tauopathies: new perspectives and challenges","volume":"17","author":"Zhang","year":"2022","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ejphar.2025.177644_bib93","doi-asserted-by":"crossref","DOI":"10.1002\/alz.077322","article-title":"Design of a phase 2, randomized, Double\u2010blind, placebo\u2010controlled, parallel\u2010group study to assess the efficacy, safety, and tolerability of BIIB080 in subjects with mild cognitive impairment due to alzheimer's disease or mild alzheimer's disease dementia","volume":"19","author":"Ziogas","year":"2023","journal-title":"Alzheimer's Dementia"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992500398X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992500398X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T16:06:38Z","timestamp":1750435598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001429992500398X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":93,"alternative-id":["S001429992500398X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177644","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antisense oligonucleotides: A promising advancement in neurodegenerative disease treatment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177644","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"177644"}}